Matthew Broadus

Matthew Broadus has a wealth of experience in the field of drug discovery and development. Matthew began their career in 2013 as a Postdoctoral Fellow at Vanderbilt University Medical Center, where they designed, executed, and managed research programs investigating the regulation of Notch intracellular domain (NICD) protein turnover. During their time there, they also optimized and executed luminescent-based small molecule kinase inhibitor screens using the cell-free Xenopus egg extract system. In 2014, they moved to Harvard Medical School, where they worked as a Postdoctoral Fellow. During this time, they designed, executed, and managed multiple research projects that investigated regulation of Hedgehog signaling. Matthew also optimized protocols for mammalian cell-based, fluorescence reporter, CRISPR/Cas9 and doxycycline inducible genetic screens. From 2017 to 2018, they worked at the Broad Institute of MIT and Harvard as a Research Scientist. In this role, they led early target prioritization and validation for CRISPR/Cas9 genetic screens aimed to identify novel mitochondrial/OXPHOS regulatory mechanisms with potential for therapeutic development against rare and aging related diseases. Finally, they worked at Casma Therapeutics from 2018 to the present, where they have held the roles of Director of Discovery Biology, Senior Scientist II of Drug Discovery Biology, Senior Scientist of Drug Discovery Biology, and Scientist II of Discovery Biology.

Matthew Broadus earned a Bachelor of Science - BS in Biomolecular/Biochemistry, Biology, and Chemistry (triple major) from Illinois State University between 2001 and 2006. Matthew then went on to pursue a Doctor of Philosophy - PhD in Cell and Developmental Biology from Vanderbilt University between 2006 and 2012.